Key result
Incidental covert cerebrovascular disease is linked to just a ~9% increase in statin initiation.
Why the study?
Does the identification of incidentally discovered covert cerebrovascular disease increase statin prescription in patients age ≥50 without prior stroke, TIA, or dementia?
Cohort (n=241,050)
Does the identification of incidentally discovered covert cerebrovascular disease increase statin prescription in patients age ≥50 without prior stroke, TIA, or dementia?
Answers are grounded in this paper and cite their sources.
The incidental discovery of covert cerebrovascular disease on neuroimaging rarely leads to new statin prescriptions in routine clinical practice, highlighting a potential gap in preventive care.
Introduction: While incidentally discovered covert cerebrovascular diseases (id-CCD) are associated with future stroke, it is not known if patients with id-CCD are prescribed statins. Methods: Patients age ≥50 with id-CCD on neuroimaging from 2009 to 2019 with no prior ischaemic stroke, transient ischaemic attack or dementia were identified using natural language processing in a large real-world cohort. Robust Poisson multivariable regression was used to assess statin prescription among patients without prior statins. Results: Among 2 41 050 patients, 74 975 patients (31.1%; 4.7% with covert brain infarcts (CBI); 29.0% with white matter disease (WMD)) had id-CCD. 53.5% (95% CI 53.2 to 53.9%) were not on statins within 6 months prior to the scan. Of those, 12.0% (95% CI 11.7 to 12.3%) were prescribed statins in the next 6 months compared with 9.3% (95% CI 9.1 to 9.4%) in those without CCD, a 2.7% (95% CI 2.4 to 3.1%) absolute increase in statin prescription for those with id-CCD. In adjusted analyses, the presence of id-CCD was only associated with minor increases in statin prescription (CBI or WMD (risk ratio (RR) 1.09, 95% CI 1.05 to 1.13), CBI alone (RR 1.34, 95% CI 1.21 to 1.47), WMD alone (RR 1.05, 95% CI 1.01 to 1.09), and CBI and WMD (RR 1.23, 95% CI 1.12 to 1.35)). Discussion: Identification of id-CCD is not associated with substantial changes in statin prescription in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Leung et al. (2024) conducted a cohort in Incidentally discovered covert cerebrovascular disease (id-CCD) (n=241,050). Incidentally discovered covert cerebrovascular disease (id-CCD) vs. No covert cerebrovascular disease was evaluated on Statin prescription within 6 months among patients without prior statins (RR 1.09, 95% CI 1.05 to 1.13). Incidentally discovered covert cerebrovascular disease was associated with only a minor increase in statin prescription within 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: